Science & Technology
The Science of Getting There First
Every drug in development faces the same fundamental challenge: getting the right molecule to the right place in the body, at the right time. For neurological conditions, that challenge is especially acute — the brain is one of the most protected organs in the human body, shielded by a barrier that blocks most drugs from ever reaching it.
The Blood-Brain Barrier Problem
Why Most Drugs Never Reach the Brain
The blood-brain barrier is the brain’s natural defense system — a tightly regulated network of cells that prevents harmful substances from entering. It’s also the reason most pharmacological treatments for neurological conditions either fail to work or require high systemic doses that cause unacceptable side effects.
Traditional drug delivery — oral pills, intravenous infusions, injections — relies on systemic circulation to transport medicine through the body. For most CNS drugs, the result is low brain uptake, high systemic exposure, and a long list of side effects.
Our Approach: Intranasal Direct-To-Brain Delivery
Bypassing the Barrier. Targeting the Brain.
Our proprietary intranasal delivery platform routes therapeutics directly to the brain via the olfactory and trigeminal nerve pathways — two neurological highways that connect the nasal cavity to the brain without crossing the blood-brain barrier.
The result: rapid brain distribution, minimal systemic exposure, and targeted action exactly where it’s needed.
The Intranasal Device
Purpose-Built for Where Care Happens
Our intranasal delivery device isn’t an adapted consumer product. It’s a purpose-engineered, single-use medical device designed for the environments where concussion occurs — emergency rooms, sports sidelines, military settings, and first-responder units.
One-step activation — no training or coordination required.
Ensures delivery to the target pathway — not swallowed or inhaled.
No power, refrigeration, or complex preparation required.
No needles, no IVs — patients remain alert throughout treatment.
Consistent, reproducible delivery across patient populations.
Proprietary asset with commercial exclusivity alongside drug compound portfolio.
The Science Behind ONP-002
A Neurosteroid Designed for Brain Injury
ONP-002 is a first-in-class intranasal neurosteroid engineered to interrupt the damaging biological cascade triggered by concussion — inflammation, oxidative stress, and swelling — at its source.
Modulates inflammatory pathways at the cellular level, limiting post-injury damage cascade.
Neutralizes free radicals that damage neurons and surrounding tissue.
Reduces brain swelling that compresses neural tissue and impairs function.
Activates mechanisms that remove damaged material before it causes further harm.
Supports the brain’s own protective systems during the acute injury phase.
Enhances absorption through nasal mucosa for rapid uptake and fast brain distribution.
Clinical Validation
The Science Has Been Tested
ONP-002 is not a theoretical compound. The safety and delivery science has been validated in human clinical trials.
- Safe and well-tolerated — zero serious adverse events
- Rapid brain distribution confirmed via intranasal delivery
- Minimal systemic exposure — the drug reaches the brain, not the body
- Strong tolerability across all ascending dose cohorts
- 40-patient randomized, placebo-controlled trial underway in Australia
- First dose within 12 hours of concussion
- Twice daily treatment for 5 days post-injury
Platform Potential
One Platform. Multiple Neurological Conditions.
The intranasal delivery platform underlying ONP-002 is not a single-use asset. The same proprietary technology that delivers ONP-002 directly to the brain has potential applications across a broad range of neurological conditions — from acute emergencies to chronic neurodegenerative diseases.
The nasal drug delivery market is projected to exceed $125 billion by 2030, with neurological applications representing one of the fastest-growing segments.
In collaboration with Receptor.AI, we are accelerating the exploration of additional CNS indications using AI-driven drug discovery — building a diversified pipeline on top of a validated delivery platform.